Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,652 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 35 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: isradipine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Type 2 Diabetes Mellitus
Interventions: Stayers, Switchers; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine, Quetiapine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Bipolar I Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more

Conditions: Treatment-resistant Schizophrenia
Interventions: Clozapine, Antipsychotics,Other (non-Clozapine); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more

Conditions: Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 45 Years
Enrollment: 277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia
Interventions: 2-way pager, Treatment as usual; Device · Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Schizo Affective Disorder
Interventions: rTMS; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia / Schizoaffective Disorder
Interventions: Cognitive Training, Mobile cognitive training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Affective Disorders, Psychotic
Interventions: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP), Health & Wellness (H&W); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Sensory Gating
Interventions: Aripiprzole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Psychosis, Schizophrenia, Genetic Structure, Childhood Onset Psychotic Disorders, Schizoaffective Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 6 Years and older
Enrollment: 1,556 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1984 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia
Interventions: Self-management program for chronic illness; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Interventions: stg-rt-fMRI-Neurofeeback, sham-rt-fMRI-Neurofeedback; Other
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Brockton, Massachusetts

Conditions: Schizophrenia
Interventions: Placebo, Risperdal; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Schizophrenia
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Social skills and symptom management training; Procedure
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Bridgeport, Connecticut • Westport, Connecticut

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Capsule with folate, Vitamin B12 & pyridoxine, placebo; Dietary Supplement · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Schizophrenia
Interventions: Interactive Website on management of schizophrenia, Written materials and video on management of schizophrenia; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Intervention Active tDCS; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

Antipsychotic Response in Schizophrenia

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

State Representation in Early Psychosis

Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

A Cognitive Mobile Intervention for Motivation in Psychotic Disorders

CBT-CP for Veterans With SMI

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia

A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

TMS Enhancement of Visual Plasticity in Schizophrenia

Enhancing the Outcome of Skills Training for People With Schizophrenia

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

Effectiveness of an Interactive Educational Website for Improving the Quality of Mental Health Care for People With Schizophrenia

Transcranial Direct Current Stimulation (TDCS) for Auditory Hallucinations in Early Onset Schizophrenia (EOS)